A Strategic Comparison: Whole Genome Sequencing (WGS) or a Polygenic Risk Score (PRS)?
In this article
Understanding the gulf between "Diagnostic Certainty" and "Statistical Probability" in health technologies. Data bias in the Turkish population, cost-effectiveness analysis, and the right investment architecture for the health platforms of the future.
Introduction: The Biggest Data Strategy in Medical History
Modern medicine is moving away from the centuries-old approach of treating symptoms and toward a predictive and preventive model. The fuel for this transformation is "Genomic Data." Yet today, when establishing a health app, hospital, or biotechnology startup, we face an enormous strategic crossroads: WGS (Whole Genome Sequencing) or PRS (Polygenic Risk Score)?
This is not a simple choice of technology; it is the answer to what you promise your users. Will you offer them a definitive, lifesaving "Diagnosis," or a "Probability Calculation" advising them to change their lifestyles? Especially in a genetically diverse region such as Türkiye, this decision is vital to scientific validity and ethical responsibility. This feature analyzes every layer of the two approaches, from the molecular level to the economic level.
Genomic Literacy Glossary
1. The Fundamental Difference: Deterministic vs. Probabilistic Approaches
As an oncologist, when I sit across from a patient, the strength of the data I have determines my treatment decision. WGS and PRS are in different leagues in terms of clinical reliability.
2. The "Elephant in the Room": Data Bias and the Turkish Population
If your app targets the Turkish market, there is a very serious scientific barrier (bias) to using PRS. The rule in genetics is this: Your results are accurate only for the race whose data you used to train your algorithm.
The "Blind Spot" of PRS Models
The overwhelming majority of global genomic databases (GWAS - Genome Wide Association Studies) consist of individuals of European ancestry (UK Biobank, Icelandic data, etc.).
Turkish society is a highly diverse population combining Asian, European, and Middle Eastern gene pools. A PRS model trained on British data may give a Turkish individual false reassurance by reporting "Low Risk" (False Negative), or conversely create unnecessary anxiety. Since WGS preserves the "Raw Data," it offers the opportunity to reanalyze the data as Turkish scientists (TÜSEB) develop local PRS models.
3. The Hierarchy of Clinical Utility
How much "usable" information do you offer a user in a wellness app? This is where the superiority of WGS emerges.
Definitive Diagnosis. Saves Lives. (Example: Cancer Genes)
Drug Response. Actionable Results in 99% of Individuals.
Lifestyle Advice. Probability Calculation.
WGS covers the entire pyramid. PRS/Array methods can provide only the bottom layer.
4. Strategic Decision Matrix: Cost vs. the Future
Investors often say, "WGS is very expensive." Yet considering "Data Lifespan," inexpensive PRS technology is actually more costly because it is single-use.
| Feature | PRS Only (Genotyping Array) | Whole Genome (WGS) | Strategic Commentary |
|---|---|---|---|
| Initial Cost | Low (~$50) | High (~$200-300) | The barrier to entry for PRS is low, but the data lack depth. |
| Data Lifespan | Single-Use | Lifelong (Asset) | WGS data are generated once and queried repeatedly as science advances (Sequence Once, Query Often). |
| Rare Variants | DOES NOT DETECT | DETECTS | Only WGS captures rare variants specific to the Turkish population. |
| Drug Guide (PGx) | Very Limited | Full Coverage | WGS answers the user's question, "Which drug should I take?" |
| Future Compatibility | Low | High | If a new gene is discovered tomorrow, it is already present in WGS data. PRS requires a new test. |
DROZDOGAN Academy Commentary
Digitalization in healthcare means not merely developing an app but building an architecture of trust . There is no doubt that Polygenic Risk Scores (PRS) will be a very valuable tool for "risk stratification" in the medicine of the future. But today, offering a Turkish citizen a risk score calculated from a British database means selling them "maybes."
If our goal is to offer users tangible, actionable, lifesaving benefits (for example, "This painkiller will not work for you" or "You have inherited high cholesterol; screen your family too"), then WGS (Whole Genome Sequencing) is a necessity, not a luxury.
My recommendation is this: Invest not in technology but in "Raw Data" . Obtain the raw data with WGS; even as algorithms (PRS) change, improve, or become localized over time, the data in your hands will always remain your most valuable treasure. Build the medicine of the future on "facts," not "maybes."
- Frontiers in Genetics (2025): Elective genomic screening: results of the implementation of a whole genome sequencing program at a medical check-up unit. Access Link
- ResearchGate (2026): Prevalence of actionable pharmacogenetic variants and high-risk drug prescriptions: A Swiss hospital-based cohort study.
- PubMed (2022): The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review. Access Link
- Nebula Genomics (2025): 30x Whole-Genome Sequencing vs WES vs Panels. Technical Report
- ACMG Guidelines (2026): Evidence-Based Clinical Practice Guidelines & Secondary Findings v3.2. ACMG Portal
- NIH BabySeq Project: Implementation of Genome Sequencing as Screening in Infants. NCBI Record
- KVKK Guide: Guide on Considerations for Processing Genetic Data (Current Draft). KVKK Official Website
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.